202216 Jun

PIPRA concludes CHF 2.1 million seed round

Summary

Based in Zurich, PIPRA has developed a CE-certified AI-based pre-operative test to assess a patients risk of suffering from cognitive disorders after surgery. The technology leverages the startups carefully curated and harmonized patient database to calculate an individual and reliable risk score of presenting POD. Today, doctors make a subjective assessment of a patients risk which can lead to errors and misinformation for the patients.Multiple hospitals rely on PIPRAThe PIPRA tool is CE-certified. Further award prizes have followed since then.PIPRA proposes a new tool that allows rapid determination of an individual patients risk to develop postoperative delirium after an operation. We will finally be able to not only target resource-intensive non-pharmacological preventive interventions to those patients who benefit the most, but we will also be able to design clinical trials regarding delirium based on risk groups.

Source: Startupticker

Funding

$2.11M
Amount
Jun 16 2022
Date
-
Investor
Pipra
Company

Classifications

Companies